SCD Impairs T-Cell Function in Cancer
METHODOLOGY:
Researchers analyzed CD8+ T cells from peripheral blood mononuclear cells of healthy donors and patients with SCD, examining chromatin architecture changes through Hi-C technology and DNA fluorescence in situ hybridization (FISH).
Analysis included CD34+ hematopoietic stem cell–engrafted humanized mice with high human leukocyte engraftment showing over 75% human CD45+ leukocytes for RMC2C1 cell implantation studies.
Treatment protocols involved administration of 10 mg/kg GYY4137 intraperitoneally twice weekly for 3 weeks, followed by anti–programmed cell death 1 (PD-1) antibody treatment at 200 μg per mouse twice weekly.
TAKEAWAY:
CD8+ T cells from patients with SCD exhibited reduced SLC7A11 expression and increased lipid peroxidation compared with healthy control individuals, with a significantly decreased H2S concentration in serum samples ( P < .0001).
< .0001). GYY4137 treatment restored SLC7A11 chromatin interactions and enhanced immune function, with combination therapy showing improved antitumor efficacy ( P < .0001).
< .0001). Analysis revealed reduced long-range chromatin interactions in SCD CD8+ T cells, particularly affecting genes involved in H2S biosynthesis including CBS and CTH .
and . Treatment with GYY4137 and anti–PD-1 increased tumor-resident CD8+ T-cell infiltration ( P < .0001) and boosted cytotoxic activity through higher percentages of granzyme B+ CD8+ T cells.
IN PRACTICE:
'Our study revealed that SCD altered CD8+ T cell 3D genome architecture, triggering ferroptosis and weakening antitumor immunity, thereby promoting tumor growth. Using murine and humanized SCD models, we found that disrupted chromosomal interactions in CD8+ T cells reduced the expression of antiferroptotic genes, including SLC7A11 and hydrogen sulfide (H2S) biogenesis genes, thereby increasing susceptibility to ferroptosis. Therapeutic restoration of H2S concentration in SCD mice rescued SLC7A11 expression, mitigated ferroptosis, and enhanced immune and antitumor responses,' the authors of the study wrote.
SOURCE:
This study was led by Zilong Zhao, The University of Texas MD Anderson Cancer Center in Houston. It was published online on May 12 in Immunity .
LIMITATIONS:
According to the authors, while Hi-C and DNA FISH analyses revealed chromatin interaction changes in CD8+ T cells under SCD conditions, altered T-cell subtypes and states may contribute to these findings. The researchers noted that while this study highlights SCD's impact on ferroptosis and chromatin architecture, other tumor microenvironment–related factors remain to be examined. Additionally, the use of peripheral blood mononuclear cell–derived humanized mice may limit insights into early immune development and influence the robustness of tumor growth differences.
DISCLOSURES:
This study was supported by grants from National Institutes of Health, Cancer Prevention and Research Institute of Texas, and Department of Defense. Pavlos Msaouel received funding from Gateway for Cancer Research, the Kidney Cancer Association, the V Foundation, and the MDACC Physician-Scientist Award. Additional disclosures are noted in the original article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Centene raises Wall Street optimism that Medicaid insurers can improve profits
By Amina Niasse NEW YORK (Reuters) -Wall Street regained confidence in Medicaid insurers after Centene said on Friday it expects to be able to raise rates charged to states for 2026 health plans for low-income Americans and strengthen profit margins. Insurer shares rose across the board. Centene shares were up 5% in early afternoon trading after falling 16% on the company's announcement of a second-quarter loss and forecast cut. Rivals UnitedHealth, CVS Health and Humana rose 1.61%, 2.69% and 3.45%, respectively. All three report earnings next week. Centene in an earnings call reassured investors it would work with states to ensure their payments for Medicaid plans match the company's increased medical costs for 2026. 'Our goal is to reprice 100%' of plans, said company CEO Sarah London. Insurers are paid a set amount by states for Medicaid plans, which are jointly funded with the federal government. Centene, UnitedHealth and Elevance have said this year that state reimbursements for these plans have lagged behind actual costs of care. Cautious investors have been looking for Medicaid health plan design changes and strategic geographic changes by the companies to reduce use of healthcare services. New work requirements for Medicaid recipients in President Donald Trump's signature tax-cut and spending bill have made some investors worry that healthy people could disenroll in coming years. The bill requires states to verify certain members are working or volunteering a minimum of 80 hours per month to qualify for Medicaid coverage starting in 2027. After a COVID-19 era requirement to keep people enrolled expired in 2023, Medicaid plans redetermined each person's eligibility. This pushed members off, changing the mix of sick and healthy participants, and some Medicaid insurers struggled. 'The Medicaid redeterminations have proven to be far more disruptive than anyone thought," said Jeff Jonas, a portfolio manager at Gabelli Funds. "The entire industry is focused on restoring margin over winning new contracts and membership." More detailed data could justify midyear price increases, said Kevin Gade, chief operating officer at Bahl & Gaynor, and correct mismatched rates set by states after the pandemic. More data over the next year will also enable insurers to improve cost management techniques and raise rates paid by states, Gade said. "With enough data you can take care of the problem.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fox News
6 minutes ago
- Fox News
Otters beat the heat with frozen fish treats at Memphis Zoo
At the Memphis Zoo, otters beat the Tennessee heat with frozen fish treats that are part snack, part cooling enrichment.
Forbes
6 minutes ago
- Forbes
The Prototype: Bringing Advanced Semiconductor Manufacturing Back To The U.S.
In this week's edition of The Prototype, we look at a federal program to bring advanced semiconductor R&D to Florida, a quantum computing milestone for biotech, a new way to get forever chemicals out of the water supply and more. You can sign up to get The Prototype in your inbox here . Florida Semiconductor Engine T he tech sector drives the U.S. economy, which in turn is undergirded by the semiconductor chips that power servers, computers, phones and more. Even though these chips are mostly designed domestically, they're not made in America: Nearly 90% are imported. That's an issue that Tawny Olore wants to help fix. She's the CEO of the Florida Semiconductor Engine, one of 10 regional networks backed by a two-yer, $15 million grant from the National Science Foundation. Half of that money is going towards research and development, for which it has five major projects. These include developing improved hardware security, designing 6G chips for the next generation of mobile internet and a project to build cryogenic, superconducting chips for AI and other forms of advanced computing. The other half of the spend is geared towards workforce development programs to ensure that there are people with the skills needed for the jobs the Engine hopes to bring back to the U.S. For example, it helped to develop an Associate's Degree for semiconductor engineering at Valencia College. The program, which is enrolling its first students this Fall, will train students to work in cleanrooms and operate the delicate equipment used to make chips. 'That's really important and shouldn't be diminished by the research and development projects that are so cool,' Olore said. 'You've got to have people there to be able to fill those jobs.' Stay tuned. IBM ran its simulation of mRNA structures on its Heron quantum processor. IBM L ast month, IBM rolled out its framework for building a 'fault-tolerant' quantum computer–one that can solve practical problems with low rates of error caused by the physics of its operations–by 2029. One major part of that is understanding what business problems exist that quantum computing can play a role in solving, Jamie Garcia, director of algorithms and partnerships at the company, told me. One potential: drug development. IBM has been working with biotech company Moderna since 2023, finding new techniques to predict the structures of messenger RNA (mRNA), which is at the core of Moderna's Covid vaccine and a number of other therapies it's developing. Figuring out how to use mRNA, which helps tell your body which proteins to make, is a complicated process. There are countless ways to code mRNA to make the same protein. For the Covid vaccine, for example, there are about 10^623 different possibilities. But the code is not enough–the order in which that code is arranged also affects how the final mRNA molecule is physically structured, which affects things like how durable it is and how large or small a dose might be–that's crucial for what arrangement will work best as a drug. 'That is sort of a combinatorial optimization issue that blows up really big, really fast,' Garcia said. For conventional computers, it would take centuries to solve them with brute force–even using AI models–because the hardware has to consider each possibility one at a time. That forces programmers to use shortcuts by simplifying the math to rougher approximations. A quantum computer, by contrast, can tackle portions of the problem in parallel–which makes for ultimately better calculations. Using quantum algorithms based on ones IBM had previously developed for financial problems, the two companies were able to successfully predict the structure of an mRNA sequence that was about 60 nucleotides long, which is at the upper limit of what a conventional computer can do. While that's much smaller than the sequences used for drugs, Garcia said that IBM's quantum computer will be able to predict bigger and bigger structures as the company builds out its capabilities. 'We're really excited about these results,' she said. 'And I think we're just going to keep finding the next generation of algorithms to really start checking the box when it comes to RNA problems.' DISCOVERY OF THE WEEK: NEW MATERIAL CLEANS FOREVER CHEMICALS FROM WATER Researchers at the University of Utah have invented a new material that can clean Perfluorooctanoic acid (PFOA) from water sources. PFOA belongs to the family of 'forever chemicals' that can contaminate soil and water without breaking down, and exposure to it can cause cancer. The new zirconium-based material not only attracts and absorbs PFOA, it also lights up when it does so, letting any engineers know that the forever chemical is present in a body of water. The cleaning material is also reusable–PFOA can be removed with conventional processes. This combination 'makes it a versatile and practical solution for water treatment and environmental monitoring,' lead author Rana Dalapati said in a statement. FINAL FRONTIER: SOUTH KOREA PLANS A MOON BASE In a public hearing earlier this week, South Korea's space agency laid out a roadmap for its exploration of space, The Korea Times reported. The agency is making its own plans to establish a permanent moon base by the year 2045. To help it get there, it will develop its own capabilities to launch and land humans on the lunar surface by 2040. WHAT ELSE I WROTE THIS WEEK In my other newsletter, InnovationRx, Amy Feldman and I looked at Sarepta's showdown with the FDA over its gene therapy for Duchenne Muscular Dystrophy, the FDA's new top drug regulator, a biotech company's strategy to fight cancer, a startup's therapy chatbot, and more. SCIENCE AND TECH TIDBITS Astronomers found an object in the outer solar system that seems to be moving in sync with Neptune. About 56 miles in diameter, it circles the Sun once for every ten times it takes the eighth planet. The orbits are in sync at this ratio despite being millions of miles apart, something that hasn't been seen before by scientists. Researchers at the University of California, Riverside have discovered a way to repair DNA that's been damaged by environmental stress, which could one day lead to prevention of afflictions like arthritis and inflammatory bowel disease. Around 10 million people live with HTLV-1 infection, which can lead to inflammatory diseases or even forms of cancer, but it currently has no treatments or vaccines. However, new research with mice suggests that existing HIV drugs could help prevent both transmission and disease. Street noise is one of the most annoying parts of city life, but Swiss scientists may have a solution: they've invented a mineral foam that can dampen street noise and is easier to install, since it's about four times thinner than conventional sound absorbers. PRO SCIENCE TIP: GET YOUR 7,000 STEPS A DAY It's long been a common rule of thumb to aim for 10,000 steps a day for optimal health, which can be a challenge for those who are stuck at their desks for work all day. But a new study suggests that you can get the same benefit with nearly one-third fewer steps. In a review of 57 different studies conducted in over ten countries, the researchers' analysis found walking around 7,000 steps a day reduced the risk of dementia and type two diabetes, and had other benefits as well. Which is not to say that getting 10,000 steps a day is bad–but 7,000 seems to represent an inflection point: the benefits accumulate quickly up to that point. Beyond it, the health benefits are more modest. WHAT'S ENTERTAINING ME THIS WEEK This month marks the 100th anniversary of the 'Scopes Monkey Trial'—in which schoolteacher John T. Scopes was found guilty of violating a Tennessee law that prohibited teaching the theory of evolution. So I kicked back and watched Inherit the Wind , Stanley Kramer's adaptation of the play of the same name, which is a fictionalized version of the Scopes trial. It's an absolutely mesmerizing courtroom drama that's still painfully relevant today, featuring a thunderous performance by Spencer Tracy as defense attorney Henry Drummond. It's streaming on Amazon Prime right now. MORE FROM FORBES Forbes South Park's Creators Are Now Billionaires By Matt Craig Forbes How Jeffrey Epstein Got So Rich By Giacomo Tognini Forbes Chicago's Kumiko Named World's Best Bar At 2025 Spirited Awards By Michael Solomon
